Skip to Content

Cellmid Ltd CDY

Rating as of

Morningstar’s Analysis

Valuation
Currency in AUD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Cellmid Ltd develops and sells differentiated and clinically validated solutions for a range of conditions associated with aging. The company's operating segment includes Diagnostics Cellmid/Lyramid Australia and Consumer Health which includes Advangen Australia; Advangen USA and Advangen Japan. It generates maximum revenue from the Consumer Health segment.

Contact
55 Clarence Street, Suite 204, Level 2
Sydney, NSW, 2000, Australia
T +61 292216830
Sector Healthcare
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Jun 30, 2022
Stock Type
Employees